Study design
stage IIIA-N2 NSCLC
The EMERGING-CTONG 1103 study was a multicentre (17 centres in China), national, open-label, phase II, randomised controlled trial for comparing erlotinib with GC as neoadjuvant/adjuvant therapy in patients with stage IIIA-N2 NSCLC and exon 19 or 21 